Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brown-Forman Corporation Class B (BF.B) vs McKesson Corporation (MCK) Price & Performance

Brown-Forman Corporation Class BTrade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

Brown-Forman Corporation Class B vs McKesson Corporation — how do they compare? Brown-Forman Corporation Class B trades at $28.01, while McKesson Corporation trades at $899.06 (market cap $102.58B). The key difference: McKesson Corporation pays a 0.43% dividend while Brown-Forman Corporation Class B pays none. Which is the better fit depends on your goals.

BF.BMCK
Sector
Consumer StaplesHealth
52-Week High
$31.26$995.69
52-Week Low
$22.80$659.01
Market Cap
$102.58B
Enterprise Value
$109.12B
Dividend Yield
0.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brown-Forman Corporation Class B

BF.B trades at $28.52, up 0.88% today, with a bullish technical signal from moving averages and strong trend strength (ADX). Earnings have beaten estimates in three of the last four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 forecast. The stock faces mixed analyst sentiment but shows consistent fundamental performance.

The outlook is cautiously optimistic given recent earnings strength, though limited analyst coverage and mixed ratings suggest uncertainty. Key risks include execution challenges and market volatility. Upside potential hinges on sustained earnings growth and broader market conditions.

McKesson Corporation

McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.

Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.

Returns comparison

Trailing returns across standard periods

About Brown-Forman Corporation Class B

Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.

Read more on BF.B

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK